STOCKS TELEGRAPH

Tag: Arbutus Biopharma

  • Arbutus Biopharma Corp. (ABUS) Stock on a Consistent Rise, Here’s Why

    Arbutus Biopharma Corp. (ABUS), a biopharmaceutical company, has gained an increase of 2.39% in aftermarket trading session. Consequently, ABUS is trading at $4.72 at the time of the writing. On Wednesday, ABUS closed the day at $4.61 after soaring 44.06% during the mid-day session. The mammoth increase was attributable to the positive preliminary data depicting safety of Capsid Inhibitor, AB-836.

    Why ABUS Stock Surged

    On Wednesday, ABUS announced the preliminary data from its ongoing phase 1a/1b clinical trial. The trial demonstrated that the company’s next-generation Capsid-Inhibitor, AB-836, is safe and well-tolerated in both healthy subjects and patients with cHBC. It also provided a robust antiviral activity. The phase 1a/1b trial was conducted to evaluate the safety and tolerability and antiviral activity of single and multiple doses of AB-836 in the healthy subjects and the patients having cHBC.

    Operational Results for Q3 2021

    On 4th November, ABUS released the operational results for the third quarter of the fiscal year 2021. The quarter ended on 30th September. The company generated total revenue of $3.34 million during the quarter against $1.52 million during the same quarter of 2020. The company suffered a loss of $18.4 million from the operations during the quarter against $15.2 million for the same quarter of 2020. The net loss suffered by the company during the period was $19.15 million (or $0.24 per basic and diluted share) against $18.75 million (or $0.27 per basic and diluted share) for the same period of 2020.

    Executive Commentary

    William Collier, President and Chief Executive Officer of ABUS, while commenting on the results said that the company is impressed with the continued development of HBV. These assets align with its novel three-pronged approach to develop an HBV functional via suppressing HBV DNA. He hoped that the company would continue to bring further improvements in its financial stature during upcoming quarters.

    Future Outlook for ABUS

    The last three months have seen ABUS stock surge by more than 30%. Most of that increase was on account of positive developments related to the stock in the form of research results for AB-836. Analysts are confident that the company is in a good position to continue this performance in near future.

  • Why Is The ABUS Stock Up Before The Market Opens Today?

    The stock of Arbutus Biopharma Corporation (ABUS) was trading at $2.97 in pre-market trading hours on Wednesday, up 1.37%. Arbutus stock lost -0.68% last session to finish at $2.93. There was a price range of $2.83 to $2.98 for ABUS stock. ABUS traded 1.75 million shares, which was almost equal to its daily average of 1.77 million shares over the past 100 days. ABUS stock is rising following news that it has been given permission to submit an Investigational New Drug application (IND).

    What was ABUS IND for?

    As a biopharmaceutical company, Arbutus’ primary objective is to discover, develop, and commercialize treatments for chronic Hepatitis B virus (HBV) infections. ABUS believes that multiple product candidates with different mechanisms of action can provide a new treatment regimen for chronic HBV infection, which ABUS is developing. ABUS has also begun to develop drugs to treat coronaviruses including COVID-19.

    According to Arbutus press release today, the Food and Drug Administration (FDA) gave its approval for the company to proceed with its Investigational New Drug (IND) application for AB-729 in a Phase 2a clinical trial.

    • ABUS will evaluate AB-729 in Phase 2a clinical trial as a proof of concept for CHB patients in conjunction with continuous nucleos(t)ide analog (NA) therapy and short treatments of peg- IFNα -2a.
    • As a cornerstone therapy for patients with CHB, the acceptance of AB-729’s IND application is a significant step forward for ABUS.
    • As a result, ABUS is now focusing initiating this proof-of-concept Phase 2a clinical trial in current quarter.
    • A new IND submission by ABUS is being reviewed and is deemed safe to proceed in patients with chronic hepatitis B virus infection.
    • As part of this Phase 2a trial, ABUS is investigating whether short courses of Peg-IFN following HBsAg suppression and immunoreactivation via AB-729 might lead to a functional cure in chronic hepatitis B subjects without HBeAg.

    In the Phase 2a Clinical Trial:

    Arbutus (ABUS) will conduct this study to investigate the safety and efficacy of AB-729 combined with NA therapy and short courses of Peg- IFNα-2a in subjects suffering from CHB. For the trial, ABUS is expected to enroll 40 noncirrhotic, nonNA-suppressed, HBeAg-negative subjects pending protocol approval.

    ABUS will be administering AB-729 to subjects for 24 weeks, during which time they will be randomized into one of four groups. If the treatment stopping criteria are met, all subjects will continue on NA therapy for 24 weeks following completion of Peg- IFNα-2a treatment. ABUS will be intensively following the subjects up for a period of 48 weeks if subjects stop NA therapy.

  • Biotech Roundup: Nurse in New York City was first vaccinated against COVID-19

    Biotech Roundup: Nurse in New York City was first vaccinated against COVID-19

    As the U.S. reached 300,000 deaths connected with Covid-19, the first shots were given. The nurse in New York City was first vaccinated against COVID-19. On Monday, during the American mass vaccine drive, the first shot was rendered, which opened a new chapter in the fight against coronavirus’s pandemic.

    This week’s total number of shipments could exceed 2.9 million doses of Pfizer vaccine, which the FDA approved last Friday night for emergency use. A further 2.9 million supplies are eligible three weeks from now for recipients to receive a second dose.

    Phase 3 clinical trials found that the vaccine is 95 percent successful over a spectrum of age, ethnic and racial groups when administered in two doses. The first vaccination this week is obtained by front-line community staff and others who work with long-term care.

    BioCardia Inc. (NASDAQ:BCDA) shares were trading up 58.87% at $4.48 at the time of writing on Monday following the company reported that it has entered into definitive agreements with investors for the purchase and sale of 1,789,474 shares of its common stock at a purchase price of $4.75 per share in a registered direct offering priced at-the-market under Nasdaq rules.

    BioCardia Inc. (NASDAQ:BCDA) share price went from a low point around $1.91 to briefly over $6.75 in past 52 weeks, though shares have since pulled back to $4.48. BCDA market cap has remained high, hitting $60.84M at the time of writing, giving it price-to-sales ratio of more than 200.

    Rubius Therapeutics Inc. (RUBY) last closed at $8.73, in a 52-week range of $3.35 to $14.44. Analysts have a consensus price target of $10.67.

    AnPac Bio-Medical Science Co. Ltd. (ANPC) stock soar by 35.07% to $5.70 after reporting that it has made significant progress in detecting pre-cancer diseases.

    Synlogic Inc. (NASDAQ:SYBX) Shares headed rising, higher as much as 13.39% following the announcement of advancement of SYNB1891 to combination arm dosing with PD-L1 checkpoint inhibitor in the on-going phase 1 study for the treatment of solid tumors and lymphoma. The most recent rating by Oppenheimer, on August 21, 2019, is at a Perform.

    Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) rose 29.20% after gaining more than $35.33 on Monday.

    Arbutus Biopharma Corporation (ABUS) last closed at $4.88, in a 52-week range of $0.88 to $9.02. Analysts have a consensus price target of $6.40.

    Amarin Corporation plc (AMRN) stock soar by 1.60% to $5.09 after announcing the presentation of important VASCEPA® (icosapent ethyl)-related scientific findings during the National Lipid Association (NLA) Scientific Sessions 2020. The most recent rating by JP Morgan, on September 29, 2020, is at a Neutral.

    Arvinas Inc. (NASDAQ:ARVN) Shares headed rising, higher as much as 95.06% after revealing that it is commencing an underwritten public offering of $250.0 million of its common stock. The most recent rating by Oppenheimer, on December 14, 2020, is at an Outperform.

    BioLineRx Ltd. (NASDAQ:BLRX) rose 26.97% after gaining more than $0.72 on Monday. The company on November 23, 2020 reported its financial results for the quarter ended September 30, 2020.

    Homology Medicines Inc. (FIXX) last closed at $11.97, in a 52-week range of $8.70 to $22.50.

    BioCryst Pharmaceuticals Inc. (BCRX) stock soar by 4.68% to $8.50. The firm is presenting at the JMP Securities Hematology Summit, which is being conducted as a virtual event, on Tuesday, December 15, 2020 at 3:30 p.m. ET. The most recent rating by JP Morgan, on September 29, 2020, is at an Overweight.

    BioNTech SE (NASDAQ:BNTX) Shares headed falling, lower as much as -14.95% after the company and Pfizer Inc. (PFE) declared additional data on neutralizing antibody and T cell responses from the Phase 1/2 trial with BNT162b2 conducted in Germany. The most recent rating by BofA Securities, on December 01, 2020, is at a Neutral.

    Akebia Therapeutics Inc. (NASDAQ:AKBA) rose 10.80% after gaining more than $0.31 on Monday. The firm reported the latest scheduled program of AkebiaShares, a peer-to-peer educational series for the kidney community.

    Seelos Therapeutics Inc. (SEEL) last closed at $1.28, in a 52-week range of $0.42 to $1.71 after announcing the sale of a $12.0 million senior secured convertible note and shares of Seelos common stock to investors.

    VBI Vaccines Inc. (VBIV) stock soar by 6.71% to $3.34. The company recently revealed a partnership for the commercialization of VBI’s 3-antigen prophylactic hepatitis B (HBV) vaccine in the United States, Europe, and Canada, pending regulatory approvals. The most recent rating by Raymond James, on August 27, 2020, is at a Strong buy.